| |
| |
|
| Insider
Information: |
Nashat Amir |
| Relationship: |
Director, 10% Owner |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
8 |
|
| Direct
Shares |
38,223 |
|
|
Indirect Shares
|
5,311,169 |
|
|
| Direct
Value |
$349,261 |
|
|
|
Indirect Value
|
$35,384,163 |
|
|
| Total
Shares |
5,349,392 |
|
|
| Total
Value |
$35,733,424 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
1
|
1
|
|
Stock
price went up :
|
1
|
0
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
1.0
|
-1.0
|
| Percentage
Gain/Loss : |
 89.2%
|
 -3.5%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Receptos, Inc. |
RCPT |
Director |
2013-05-14 |
0 |
2014-05-27 |
274 |
Premium* |
|
|
Fate Therapeutics Inc |
FATE |
Director |
2013-10-04 |
0 |
2019-08-01 |
11,034 |
Premium* |
|
|
aTyr Pharma Inc |
LIFE |
Former 10% Owner, Dire... |
2015-05-12 |
12,572 |
2015-05-12 |
17,638 |
Premium* |
|
|
Selecta Biosciences Inc |
SELB |
Director |
|
0 |
2019-01-25 |
2,676,234 |
Premium* |
|
|
Syros Pharmaceuticals, Inc. |
SYRS |
Director, 10% Owner |
2016-07-06 |
0 |
2016-07-06 |
48,320 |
Premium* |
|
|
Scholar Rock Holding Corp |
SRRK |
|
2023-12-27 |
25,506 |
2023-12-27 |
2,248,574 |
Premium* |
|
|
Morphic Holding, Inc. |
MORF |
Director |
2023-06-28 |
145 |
2023-06-28 |
130,153 |
Premium* |
|
|
Metacrine, Inc. |
MTCR |
Director, 10% Owner |
2020-09-18 |
0 |
2020-09-18 |
178,942 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
71 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-05-14 |
4 |
OE |
$7.73 |
$8,005,165 |
I/I |
1,035,597 |
1,035,597 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-05-14 |
4 |
B |
$14.00 |
$2,118,802 |
I/I |
151,343 |
1,186,940 |
2.1 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • • |
2013-10-04 |
4 |
A |
$0.00 |
$0 |
I/I |
1,511,407 |
1,511,407 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • • |
2013-10-04 |
4 |
A |
$6.00 |
$770,676 |
I/I |
128,446 |
1,639,853 |
0 |
- |
|
| FATE |
Fate Therapeutics Inc |
Director |
– • • |
2013-10-04 |
4 |
B |
$6.00 |
$4,999,998 |
I/I |
833,333 |
2,473,186 |
2.25 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-11-14 |
4 |
S |
$25.00 |
$3,852,225 |
I/I |
(154,089) |
1,032,001 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-11-14 |
4/A |
S |
$25.00 |
$3,852,225 |
I/I |
(154,089) |
1,032,851 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-11-14 |
4/A |
S |
$25.00 |
$3,852,225 |
I/I |
(154,089) |
58,772 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-11-15 |
4/A |
S |
$24.54 |
$373,646 |
I/I |
(15,226) |
57,931 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-11-15 |
4/A |
S |
$24.54 |
$373,646 |
I/I |
(15,226) |
1,017,625 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-11-15 |
4 |
S |
$24.54 |
$373,646 |
I/I |
(15,226) |
1,016,775 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-11-20 |
4 |
S |
$22.77 |
$698,697 |
I/I |
(30,685) |
56,237 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2013-12-06 |
4 |
S |
$26.69 |
$4,538,860 |
I/I |
(170,000) |
46,851 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2014-05-27 |
4 |
D |
$0.00 |
$0 |
I/I |
(383,100) |
386,989 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2014-05-27 |
4 |
A |
$0.00 |
$0 |
I/I |
3,827 |
3,827 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2014-05-27 |
4/A |
D |
$0.00 |
$0 |
I/I |
(23,598) |
23,253 |
0 |
- |
|
| RCPT |
Receptos, Inc. |
Director |
– • – |
2014-05-27 |
4/A |
A |
$0.00 |
$0 |
I/I |
4,335 |
274 |
0 |
- |
|
| LIFE |
aTyr Pharma Inc |
Director |
– • • |
2015-05-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,572 |
|
- |
|
| LIFE |
aTyr Pharma Inc |
Former 10% Owner |
– • – |
2015-05-12 |
4 |
A |
$0.00 |
$0 |
I/I |
1,827,992 |
17,638 |
0 |
- |
|
| SELB |
Selecta Biosciences Inc |
Director |
– • • |
2016-06-21 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
40,742 |
|
- |
|
| SELB |
Selecta Biosciences Inc |
Director |
– • • |
2016-06-27 |
4 |
A |
$0.00 |
$0 |
I/I |
1,712,695 |
1,691,963 |
0 |
- |
|
| SELB |
Selecta Biosciences Inc |
Director |
– • • |
2016-06-27 |
4 |
B |
$14.00 |
$2,100,000 |
I/I |
150,000 |
1,836,703 |
2.25 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Director |
– • • |
2016-07-06 |
4 |
A |
$0.00 |
$0 |
I/I |
1,186,653 |
22,167 |
0 |
- |
|
| SYRS |
Syros Pharmaceuticals, In... |
Director |
– • • |
2016-07-06 |
4 |
B |
$12.50 |
$5,000,000 |
I/I |
400,000 |
48,320 |
2.25 |
- |
|
| SELB |
Selecta Biosciences Inc |
Director |
– • – |
2017-09-20 |
4 |
S |
$20.03 |
$853,389 |
I/I |
(42,610) |
1,795,587 |
0 |
- |
|
71 Records found
|
|
Page 1 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
